Literature DB >> 11414310

Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis.

C M Fernández-Rodriguez1, I Prada, A Andrade, M Moreiras, R Guitián, R Aller, J L Lledó, G Cacho, J Quiroga, J Prieto.   

Abstract

Insulinlike growth factor-1 (IGF-1) is an anabolic hormone synthesized by the liver upon stimulation by growth hormone (GH). IGF-1 exerts important effects on renal hemodynamics and renal sodium handling. The bioactivity of this hormone is influenced by its binding proteins (BP) of which IGF-BP3 favors retention in the capillary lumen while IGF-BP1 facilitates the transport to the target tissues. IGF-BP1 modulates the actions of IGF-1 on target cells including renal tubules. Although a number of reports have dealt with disturbances of the IGF-1/IGF-BP system in cirrhosis, no studies have yet addressed the relationship between alterations in this system and renal function changes in cirrhosis. In the present study we have included 20 patients with cirrhosis and 10 healthy subjects (control group). As compared with the controls, patients showed lower circulating levels of IGF-1 and IGF-BP3, higher IGF-BP1 levels, and a tendency to higher insulinemia and GH values. The index IGF-1 x IGF-BP1/IGF-BP3 (IGF-1-IGF-BP index, reflecting the accessibility of circulating IGF-1 to target cells) was higher in patients with ascites. IGF-1 directly correlated with renal blood flow (P < 0.05), with IGF-BP3 (P < 0.001) and inversely with the Pugh's score (P < 0.02). A negative correlation was found between IGF-1-IGF-BP index and fractional sodium excretion (P < 0.01) and between IGF-BP1 and urinary sodium excretion (P < 0.02). Our findings support the hypothesis that the disturbance of the IGF-1/IGF-BP axis may be related to the degree of renal vasodilation and renal sodium retention in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414310     DOI: 10.1023/a:1010631800505

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  53 in total

1.  Growth hormone/insulin-like growth factor 1 axis alterations contribute to disturbed protein metabolism in cirrhosis patients after hepatectomy.

Authors:  T Inaba; H Saito; T Inoue; I Han; S Furukawa; T Matsuda; S Ikeda; T Muto
Journal:  J Hepatol       Date:  1999-08       Impact factor: 25.083

2.  Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein.

Authors:  A M Suikkari; V A Koivisto; E M Rutanen; H Yki-Järvinen; S L Karonen; M Seppälä
Journal:  J Clin Endocrinol Metab       Date:  1988-02       Impact factor: 5.958

3.  An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I.

Authors:  R G Elgin; W H Busby; D R Clemmons
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

4.  High insulin-like growth factor binding protein 1 levels in cirrhosis: link with insulin resistance.

Authors:  E Shmueli; J P Miell; M Stewart; K G Alberti; C O Record
Journal:  Hepatology       Date:  1996-07       Impact factor: 17.425

5.  Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients.

Authors:  J O Jørgensen; W F Blum; N Møller; M B Ranke; J S Christiansen
Journal:  J Clin Endocrinol Metab       Date:  1991-03       Impact factor: 5.958

6.  Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon.

Authors:  R S Sherwin; M Fisher; J Bessoff; N Snyder; R Hendler; H O Conn; P Felig
Journal:  Gastroenterology       Date:  1978-06       Impact factor: 22.682

7.  Effects of IGF-I on renal function in end-stage chronic renal failure.

Authors:  S B Miller; M Moulton; M O'Shea; M R Hammerman
Journal:  Kidney Int       Date:  1994-07       Impact factor: 10.612

8.  Differential mRNA expression of insulin-like growth factor system during renal injury and hypertrophy.

Authors:  M K Hise; L Li; N Mantzouris; R M Rohan
Journal:  Am J Physiol       Date:  1995-12

Review 9.  Insulin-like growth factor system and the kidney: physiology, pathophysiology, and therapeutic implications.

Authors:  R Hirschberg; S Adler
Journal:  Am J Kidney Dis       Date:  1998-06       Impact factor: 8.860

10.  Increase of glomerular filtration rate and renal plasma flow by insulin-like growth factor-I during euglycaemic clamping in anaesthetized rats.

Authors:  U Baumann; T Eisenhauer; H Hartmann
Journal:  Eur J Clin Invest       Date:  1992-03       Impact factor: 4.686

View more
  10 in total

1.  Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats.

Authors:  V Lorenzo-Zúñiga; C M Rodríguez-Ortigosa; R Bartolí; M-L Martínez-Chantar; L Martínez-Peralta; A Pardo; I Ojanguren; J Quiroga; R Planas; J Prieto
Journal:  Gut       Date:  2006-01-24       Impact factor: 23.059

Review 2.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

3.  A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

Authors:  Ghassan K Abou-Alfa; Marinela Capanu; Eileen M O'Reilly; Jennifer Ma; Joanne F Chou; Bolorsukh Gansukh; Jinru Shia; Marcia Kalin; Seth Katz; Leslie Abad; Diane L Reidy-Lagunes; David P Kelsen; Helen X Chen; Leonard B Saltz
Journal:  J Hepatol       Date:  2013-09-14       Impact factor: 25.083

Review 4.  Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Hend Mohamed El Tayebi; Ahmed Ihab Abdelaziz
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

5.  Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis.

Authors:  Yun-Lin Wu; Jing Ye; Shu Zhang; Jie Zhong; Rong-Ping Xi
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

6.  Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats.

Authors:  Gemma Odena; Mireia Miquel; Anna Serafín; Amparo Galan; Rosa Morillas; Ramon Planas; Ramon Bartolí
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

7.  Alterations of bone marrow sinusoidal endothelium in rat and patients with liver cirrhosis.

Authors:  Song Zhao; Ying-Mei Fu; Xiu-Fen Li; Zhan-Feng Jin; Rui-Bo Zhao; Qi Huang; Feng-Min Zhang; Wei-Hui Zhang
Journal:  Dig Dis Sci       Date:  2009-04-01       Impact factor: 3.199

8.  Insulin-Like Growth Factor I (IGF-I) Expressed from an AAV1 Vector Leads to a Complete Reversion of Liver Cirrhosis in Rats.

Authors:  Luciano Sobrevals; Mónica Enguita; Jorge Quiroga; Jesús Prieto; Puri Fortes
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

9.  Serum insulin-like growth factor-1 and its binding protein 3 as prognostic factors for the incidence, progression, and outcome of hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Jing Wang; Yu-Chuan Li; Min Deng; Hai-Yin Jiang; Li-Hua Guo; Wen-Juan Zhou; Bing Ruan
Journal:  Oncotarget       Date:  2017-07-12

10.  A Suggested Role of Human Growth Hormone in Control of the COVID-19 Pandemic.

Authors:  Mohamed Hamdy Elkarow; Amr Hamdy
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-09       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.